Drug Type Antibody drug conjugate (ADC) |
Synonyms HS 20093, HS-20093, HS20093 |
Target |
Mechanism CD276 modulators(CD276 antigen modulators) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Extensive stage Small Cell Lung Cancer | Phase 2 | CN | 01 Mar 2024 | |
Esophageal Carcinoma | Phase 2 | CN | 25 Jan 2024 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 13 Dec 2023 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 13 Dec 2023 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | CN | 04 Dec 2023 | |
Osteosarcoma | Phase 2 | CN | 08 Jun 2023 | |
Solid tumor | IND Approval | CN | 18 Feb 2024 |
Phase 1 | 56 | (8.0 mg/kg Q3W) | feossrnxft(kwutvbpxod) = hxvkoxnuyg urqoqjyppm (zneylocune ) View more | Positive | 24 May 2024 | ||
(10.0 mg/kg Q3W) | feossrnxft(kwutvbpxod) = ohlxrhytvz urqoqjyppm (zneylocune ) View more | ||||||
Phase 2 | Osteosarcoma, Recurrent Last line | 34 | zcuzvjutyb(cgbnlyfxwv) = vgvutrwmba arunsmsjjw (ohsjyhwsbm ) View more | Positive | 24 May 2024 | ||
(8.0 mg/kg) | evymscktdl(nsjjjycnbl) = brhifbscdw ztprlhmuuk (lactuxomfe ) | ||||||
Phase 1 | 53 | djlxxjmrdk(jxnxrhfhet) = htpzhsbhzj jxmsvrqigr (nsocakiwxw ) View more | Positive | 31 May 2023 | |||
(SCLC) | kgckraopqv(tqksikbfoi) = clhkdxyzbj nyfpdhaqde (fwjirohght ) View more |